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Background: To evaluate the efficacy and tolerability of a clonidine transdermal patch 
in the treatment of children with tic disorders (TD) and to establish a predictive model for 
patients.
Methods: Forty-one patients who met the inclusion criteria entered into 12 weeks of 
prospective, open, single-group, self-controlled treatment with a clonidine transdermal 
patch. The Yale Global Tic Severity Scale (YGTSS) was employed before therapy (base-
line) and at 4, 8, and 12 weeks after therapy.
results: (1) The total effect rates of treatment with a clonidine transdermal patch were 
29.27, 53.66, and 63.41% at 4, 8, and 12 weeks, respectively. Compared with the base-
line, the differences were significant at three different observation periods. (2) Compared 
to the level of 25% reduction, there were significant decreases in the score-reducing 
rate of motor tic and total tic severities at 12  weeks. (3) If the disease course was 
≤24 months and the motor tic score was <16 at the baseline, there was an effective rate 
of 100% for treatment with the clonidine transdermal patch. If the disease course was 
≤24 months and the motor tic score was >16, there was an effective rate of 57.1%. If 
the disease course was >24 months and the clinical classification was chronic TD, there 
was an effective rate of 62.5%. If the disease course was >24 months and the clinical 
classification was Tourette’s syndrome, 90% of the patients were invalid. (4) The main 
adverse events were rash, slight dizziness, and headache.
conclusion: (1) When patients were pretreated with a D2-dopamine receptor antago-
nist that was ineffective or not tolerated well, switching to a clonidine transdermal patch 
treatment was effective and safe. (2) A clonidine transdermal patch could be a first-line 
medication for mild and moderate TD cases that are characterized by motor tics.
Keywords: clonidine transdermal patch, tic disorders, children, prediction model, efficacy
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inTrODUcTiOn
Tic disorders (TD) commonly occur among youth and are classi-
fied into three types: TD, chronic motor or chronic vocal/phonic 
tics (CTD), and Tourette’s syndrome (TS). The prevalence of 
these types is 10–15, 3–4, and 1%, respectively (1). All TD are 
more common in boys than in girls (male/female ratio of approxi-
mately 4:1), and the clinical course may be transient or chronic. 
Typically, tic onset occurs in early childhood (i.e., 4–12 years), 
usually at the age of 7–8 years (2, 3). It peaks in severity and preva-
lence in preadolescence (i.e., 10–12 years) and begins to decline 
during adolescence. Approximately, one-half to two-thirds of 
adolescents with TS have a decrease in tic severity by early adult-
hood (4, 5). It is characterized by the presence of sudden, rapid, 
non-rhythmically repetitive and mainly involuntary body move-
ments (motor tics) and/or vocalizations (phonic tics). TD ranges 
in location (e.g., face and legs) and complexity (e.g., eye blinks, 
facial grimacing, jaw, shoulder shrugging, multistep movements, 
and phrases). Most TS patients also suffer from comorbid condi-
tions such as attention deficit hyperactivity disorder (ADHD), 
obsessive-compulsive disorder, or depression.
At present, the pathogenesis of TD remains unclear. Some 
scholars have suggested that D2-dopamine receptor dysfunc-
tion in the basal ganglia may be the major cause of tics. The 
principal treatment is pharmacological treatment combined 
with psychological behavior therapy, and individualization 
is emphasized (6). Many affected children or adolescents do 
not require pharmacological treatment because their tics do 
not impair social and academic functioning. When persistent 
tics impact the quality of life, social and academic function-
ing and lifetime activities and psychological behavior therapy 
fails, pharmacological treatment (e.g., D2-dopamine receptor 
antagonists, selective monoamine antagonists, alpha-2-adren-
oreceptor agonists, and other drugs) should be considered (1, 
7–10). D2-dopamine receptor antagonists, such as haloperidol 
and tiapride, are often effective but poorly tolerated, so their use 
is limited (1, 2, 11).
Recently, dysregulation of the noradrenoreceptor system has 
been suggested as the underlying pathophysiology. Exacerbation 
due to stress is a characteristic of tics (12). Clonidine, which acts 
as an alpha-2-adrenoreceptor agonist, has been used to treat 
hypertensive patients. Small doses of clonidine can alleviate tics 
by activating presynaptic autoreceptors in the locus ceruleus and 
then reducing norepinephrine release and turnover. Since the 
early 1980s, it has been reported that clonidine has beneficial 
effects in the treatment of TD (13–15), especially for patients with 
ADHD (1, 16).
A clonidine transdermal patch is a transdermo-therapeutic 
system that releases drugs at a constant speed successively for 
7  days. Compared with the ordinary preparation, a clonidine 
transdermal patch has no peak or valley plasma concentration, 
so it can achieve full efficacy and reduce adverse effects. Changing 
in weekly intervals only vastly improves compliance in children.
We analyzed the clinical data and follow-up results of 41 
patients who were pretreated for more than 2  months with 
D2-dopamine receptor antagonists using a prospective, open, 
single-group, self-controlled study. This study was undertaken 
with multiple objectives: (1) to evaluate the efficacy and tolerabil-
ity of a clonidine transdermal patch in the treatment of TD and 
(2) to establish a prediction model for subjects that can provide 
evidence-based recommendations for appropriately choosing 
clonidine transdermal patches for treatment.
sUBJecTs anD MeThODs
subjects
The inclusive criteria were as follows: (1) between the ages of 6 
and 18 years, weight more than 20 kg, normal intelligence and 
either sex; (2) met the diagnostic criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM-IV; 
American Psychiatric Association, 1994) for TD (17); (3) received 
pretreatment for more than 2 months with dopamine receptor 
antagonists but had a Yale Global Tic Severity Scale (YGTSS) 
score-reducing rate of ≤25% (18) or was not well tolerated; (4) 
written informed consent and assent were obtained from patients 
who were more than 7 years old and from their parents.
Subjects were terminated from participation in the study if 
they met one or more of the following criteria: (1) in violation 
of the study protocol during the study period; (2) lost to follow-
up during the study period; (3) unused clonidine transdermal 
patches for more than 2  weeks; (4) occurrence of any serious 
adverse events.
This study was approved by the ethics committee of the 
Children’s Hospital of Chongqing Medical University and was 
conducted in accordance with the latest version of the Declaration 
of Helsinki.
study Design and Measurements
All subjects had a comprehensive and detailed assessment of their 
current health status, which included pulse rate, blood pressure, 
respiratory rate, height, and weight, before treatment and at 
4, 8, and 12  weeks after therapy. Every subject completed the 
examination of routine hematology, routine urinalysis, liver and 
renal functions, fasting blood glucose, and electrocardiogram 
before therapy. All TD medications were discontinued before 
therapy for 1  week, and subjects entered the therapy group 
after completing the washout period. Subjects were prohibited 
from using alpha-2-adrenoreceptor blockers, antidepressants or 
other psychoactive medications, psychological behavior therapy, 
and transcranial magnetic stimulation during the study period. 
Subjects who did not want to continue to participate in the study 
because of a poor therapeutic effect were considered invalid. To 
prevent bias in the statistical results, we used the last observation 
carried forward (LOCF) to analyze the data so that we did not 
exclude these patients from the study.
The tic symptoms of each participant were evaluated by an 
appointed professional using the YGTSS (19) at baseline (after 
completing the washout period and before therapy) and at weeks 
4, 8, and 12.
The Total Tic Score (TTS) = the motor tic score + the phonic 
tic scores (range = 0–50).
The Global Severity Score (TGSS) = the motor tic score + the 
phonic tic score + overall impairment rating (range = 0–100).
TaBle 1 | changes in efficacy for the clonidine transdermal patch at different treatment stages.
Different stages effectiveness
clinical recovery (%) Obvious improvement (%) improvement (%) invalidation (%) Total rate of effectiveness (%)
4 weeks 2.44 2.44 24.39 70.73 29.27***
8 weeks 7.32 34.15 12.20 46.34 53.66***,▲
12 weeks 36.59 14.63 12.20 36.59 63.41***,▲▲
Compared with baseline, ***p < 0.001; compared with 4 weeks, ▲p < 0.05, ▲▲p < 0.01; compared with 8 weeks.
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Severity grading was divided into mild, moderate, and 
severe, and the TGSSs ranged from 0–25, 25–50, and 50–100, 
respectively.
Drug and Dosing schedule
Clonidine patches were provided by Shanxi RFL Pharmaceutical 
Co., Ltd. The drug specifications were as follows: 1.0, 1.5, and 
2.0 mg sizes. When the weights of the patients were >20 and ≤40, 
>40 and ≤60, and >60 kg, the doses of the drug were 1.0, 1.5, and 
2.0 mg per week, respectively. The clonidine transdermal patch 
was placed on the back under the shoulder blades, and the two 
sides were alternated weekly. The old patch was not removed until 
the new one had been placed for 1 day.
evaluation
Using the YGISS score that was measured after completion of 
the washout period before the therapy as the baseline score, we 
compared the score-reducing rate of four factors at three separate 
time points, including baseline and the end of weeks 4, 8, and 
12. The contents of the evaluation included the score-reducing 
rate for motor tics, phonic tics, the total tic score, and the overall 
impairment rating. The definitions were as follows
 (1)  Score-reducing rate for Motor Tic Score = (Motor Tic Score 
at baseline − Motor Tic Score at a different period)/Motor 
Tic Score at baseline × 100%;
 (2)  Score-reducing rate for Phonic Tic Score = (Phonic Tic Score 
at baseline − Phonic Tic Score at a different period)/Phonic 
Tic Score at baseline × 100%;
 (3)  Score-reducing rate for Total Tic Score =  (Total Tic Score 
at baseline − Total Tic Score at a different period)/Total Tic 
Score at baseline × 100%;
 (4)  Score-reducing rate for Overall Impairment Rating = (Overall 
Impairment Rating at baseline  −  Overall Impairment 
Rating at a different period)/Overall Impairment Rating at 
baseline × 100%.
The definition of clinical efficiency was a YGTSS score-
reducing rate of >25% reduction. We took the score-reducing 
rate of the total tic score as the judgment standard for a cura-
tive effect. Clinical recovery was defined as the score-reducing 
rate of the total tic score >75%; obvious improvement as 50% 
< score-reducing rate ≤75%; improvement as 25% < score-
reducing rate ≤50%; and clinical invalidation as score-reducing 
rate ≤25%. Clinical efficiency  =  clinical recovery  +  obvious 
improvement + improvement.
Data analyses
Statistical analysis was performed using SPSS22.0 statistical 
software package. The quantitative data were evaluated by paired 
t-tests, a one-sample t-test, and analysis of variance. The categori-
cal data were evaluated by a chi-squared test and Fisher’s exact 
probability test. We conducted the efficacy prediction for our 
data by building a decision tree. The LOCF was used as the end 
point for a participant. Statistical significance was established at 
p < 0.05.
resUlTs
A total of 41 subjects were enrolled (34 males, 7 females; male/
female ratio 4.8:1; age range 6–16 years, average 9.21 ± 2.07 years, 
median 9 years).
Clinical classifications were TD in 7 patients (7/41, 17.0%), 
CTD in 17 patients (17/41, 41.5%), and TS in 17 patients (17/41, 
41.5%).
The disease severity grading was moderate in 28 patients 
(28/41, 68.3%) and severe in 13 patients (13/41, 31.7%).
The course of the disease ranged from 2 to 109  months; 
the average was 27.36  ±  21.70  months, and the median was 
24  months. All subjects had a history of using D2-dopamine 
receptor antagonists (e.g., tiapride, haloperidol  +  artane, and 
tiapride + topamax), the course of which ranged from 2 months 
to 5+ years. Of the 41 patients, 2 dropped out of the treatment 
at 4 weeks, and 7 dropped out at 8 weeks due to inefficacy. One 
patient dropped out at 8 weeks for clinical control of tics.
curative effect analysis
At 4 weeks, clinical recovery occurred in 1 patient (1/41, 2.44%), 
obvious improvement occurred in 1 patient (1/41, 2.44%), 
improvement occurred in 10 patients (10/41, 24.39%), and 
invalidation occurred in 29 patients (29/41, 70.73%) (Table 1). 
The total efficacy rate was 29.27% (12/41). A significant difference 
(p < 0.001) was observed compared with baseline.
At 8  weeks, clinical recovery occurred in 3 patients (3/41, 
7.32%), obvious improvement occurred in 14 patients (14/41, 
34.15%), improvement occurred in 5 patients (5/41, 12.20%), and 
invalidation occurred in 19 patients (19/41, 46.34%). The total 
efficacy rate was 53.66% (22/41). A significant difference was 
observed between baseline (p < 0.001) and 4 weeks (χ2 = 5.025, 
p < 0.05).
At 12 weeks, clinical recovery occurred in 15 patients (15/41, 
36.59%), obvious improvement occurred in 6 patients (6/41, 
14.63%), improvement occurred in 5 patients (5/41, 12.20%), and 
FigUre 1 | growing method of classification and regression tree.
TaBle 2 | changes in YgTss score-reducing rate (%) at different treatment stages.
YgTss score-reducing rate Different stages
4 weeks (mean ± sD) 8 weeks (mean ± sD) 12 weeks (mean ± sD) F p
Motor tics 16.74 ± 24.75 35.55 ± 34.61▲ 46.65 ± 36.55**,▲▲▲ 8.717 0.000
Phonic tics −8.50 ± 51.69 16.68 ± 51.13 24.47 ± 57.76▲ 2.453 0.094
Total tic 8.52 ± 33.94 32.21 ± 38.19▲ 45.11 ± 41.29**,▲▲▲ 9.816 0.000
Overall impairment rating 12.19 ± 34.31 25.40 ± 37.82 37.60 ± 44.77▲▲ 4.308 0.016
Clinical effectiveness for treatment was more than 25% in YGTSS score-reducing rate; compared with the lever of 25%, derived from one-sample t-test, **less than 0.01; compared 
with 4 weeks, ▲p < 0.05, ▲▲p < 0.01, ▲▲▲p < 0.001; compared with 8 weeks.
YGTSS, the Yale Global Tic Severity Scale.
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invalidation occurred in 15 patients (15/41, 36.59%). The total 
efficacy rate was 63.41% (26/41). A significant difference was 
observed between baseline (p < 0.001) and 4 weeks (χ2 = 9.612, 
p < 0.01). There was no significant difference between the 8 and 
12  week values (χ2 =  0.804, p >  0.05). This finding suggested 
that the onset time of the clonidine transdermal patch should be 
4 weeks, and the peak time was 8–12 weeks.
all Factors of YgTss score-reducing 
rates at Different Periods
The definition of clinic efficiency was a YGTSS score-reducing 
rate for each factor that was >25% reduction. Compared with 
the level of 25% reduction, we conducted a one-sample t-test 
(p < 0.05) and found a significant difference in the score-reducing 
rate of motor tics and total tics at 12 weeks, whereas there was 
no significant difference in the score-reducing rate of phonic tics 
and the overall impairment rating at different stages (Table 2). 
Compared with 4 weeks, there was a significant difference in the 
score-reducing rate for motor tics and total tics at 8 weeks and in 
each factor at 12 weeks (p < 0.05). Compared with 8 weeks, there 
was no significant difference in the score-reducing rate for each 
factor at 12 weeks (p > 0.05). For intraobserver comparisons, there 
was some improvement in phonic tics and overall impairment 
ratings at 12 weeks, but these scores did not reach the criteria of 
clinical efficacy (25% reduction). It is suggested that a clonidine 
transdermal patch could improve motor tics but has poor results 
for phonic tics and overall impairment ratings.
Forecast analysis
We defined treatment outcomes depending on whether they 
were effective (YGTSS score-reducing rate for each factor for 
>25% reduction) as a dichotomous dependent variable. There 
were 11 independent variables (e.g., gender, onset age, age at first 
treatment, the age and weight at enrollment, the duration of the 
illness, clinical classification, comorbid ADHD, motor tic score 
at baseline, phonic tic score at baseline, and overall impairment 
rating at baseline). On that basis, we designed a four-armed deci-
sion tree to predict the conditions for effective treatment with a 
clonidine transdermal patch. The model used a classification and 
regression tree as the growing method and used the method of 
cross-validation to avoid excessive fitting. The rightness rate of 
the model was 82.9%, which indicates high predictive accuracy 
and reliability. The gain is shown in Figure 1.
The model showed the following: (1) there was a treatment 
efficacy of 100% with the clonidine transdermal patch if the 
disease course was ≤24 months and the motor tic score was <16; 
(2) there was an efficacy of only 57.1% if the disease course was 
≤24 months and the motor tic score was >16; (3) there was an 
efficacy of 62.5% if the disease course was >24 months and the 
clinical classification was CTD; and (4) 90% of patients who were 
treated with a clonidine transdermal patch were invalid if the dis-
ease course was >24 months and the clinical classification was TS. 
The importance of the independent variables in relation to treat-
ment is summarized in Figure 2. The most important variables 
were classification (100%), course of the disease (78.1%), and 
motor tics (40.4%).
safety and Tolerability evaluation
During the 12-week test period, adverse events occurred in 4.76% 
(2/41) of the subjects, but no subject withdrew from the study due 
to adverse events. One child reported a rash where the clonidine 
transdermal patch was placed, and another had a hematuria at 
week 9. The hematuria may have been unrelated to the clonidine 
transdermal patch because it disappeared before the drug was 
withdrawn.
As of June 2015, we had successfully followed up with 37 
patients. A total of 56.7% (21/37) of the patients willingly chose 
FigUre 2 | The importance of independent variables affecting treatment.
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a clonidine transdermal patch after the 12-week test ended, the 
courses of which lasted between 4 and 17 months.
A total of 38.1% (8/21) of patients who were treated with a clo-
nidine transdermal patch obtained complete remission of tics and 
were relapse free. Although 4.8% (1/21) of the patients achieved 
complete remission of tics, they recrudesced after 6 months. Our 
follow-up results showed long-term tolerability for patients with 
a clonidine transdermal patch.
There were eight cases that had adverse events during follow-
up after the end of the clinical trial. The most common adverse 
events were rash (33.3%, 7/21), slight dizziness, and headache 
(9.5%, 2/21, one combined with rash), which were mild in sever-
ity and reasonably well tolerated. There were no severe adverse 
events with regard to changes in systolic or diastolic blood pres-
sure or pulse.
DiscUssiOn
The YGTSS is the most widely used measure for treatment 
responses for tics. The YGTSS is based on the severity of motor 
and phonic tics in five separate dimensions: number, frequency, 
intensity, complexity, and interference. Each of these dimen-
sions is scored on a 0–5 scale according to tic severity. The 
total tic score (range 0–50), which consists of the symptoms 
of tics, is derived by adding the total motor tic Score (range 
0–25) and the total phonic tic score (range 0–25). The YGTSS 
also includes a separate impairment rating focused on distress 
and impairment experienced in interpersonal, academic, and 
occupational realms, the summation of which is the so-called 
overall impairment rating (range 0–50). A global severity 
score (range 0–100) is derived by summing the total motor tic 
score, the total phonic tic score, and the overall impairment 
rating. Because the overall impairment rating often remained 
unchanged over one week, the total tic score is more suitable 
for assessment of tic symptom severity. Jeon et al. (18) verified 
that a 25% reduction in the total tic score provided optimal 
sensitivity (87%) and specificity (84%) for predicting positive 
responses. Thus, we defined clinical efficacy as a YGTSS score-
reducing rate of >25% reduction. We took the score-reducing 
rate of the total tic score as a judgment standard for a curative 
effect.
A dysregulation of neurotransmission and abnormal recep-
tors is believed to be the underlying pathophysiology of tics. It 
is widely acknowledged that dopamine receptor hypersensitivity 
in the basal ganglia is the pathogenesis of TD. The dopamine 
D2 receptor antagonist has achieved the most reliable and 
fastest treatment response compared to other medications and 
is therefore the mainstay of any pharmacological treatment. 
Haloperidol, which is a typical dopamine antagonist and is 
most commonly used, may improve tic symptoms in 70–80% of 
patients (8, 20) and has an A level of evidence (21). However, this 
agent may be associated with more and more serious side effects 
than other neuroleptics. The significant adverse effects, especially 
extrapyramidal symptoms such as acute dystonia or akathisia, 
sedation, weight gain, and decline in cognitive functions, have 
led to its discontinuation. Tiapride, although associated with 
low side effects, is less effective than haloperidol and has a B 
level of evidence (21). Many studies have suggested that alpha-2 
agonists, such as clonidine, are less effective than antipsychotics 
or atypical neuroleptics, such as haloperidol, aripiprazole, and 
risperidone (10, 22, 23). We found that the effective rates of 
treatment with a clonidine transdermal patch were 29.27, 53.66, 
and 63.41% at weeks 4, 8, and 12, respectively. Compared with 
the baseline, significant changes were observed at three differ-
ent observation periods. Because our subjects were unaffected 
by or not tolerant to dopamine receptor antagonists, it can be 
6Song et al. Clonidine Transdermal Patch for Tic Disorders
Frontiers in Neurology | www.frontiersin.org February 2017 | Volume 8 | Article 32
speculated that switching to a clonidine transdermal patch may 
be effective if dopamine antagonists are ineffective or intolerable. 
The study of Du et al. (24) showed that clonidine improved tic 
symptoms in 68.31% of patients after 4 weeks of treatment and 
showed a significant change compared with placebo. Zhong 
et al. (25) reported that there were no significant differences in 
efficacy between clonidine and tiapride. In our studies, compared 
with week 4 of treatment with a clonidine transdermal patch, 
significant changes in the effective rate were observed at weeks 8 
(p < 0.05) and 12 (p < 0.01). However, there were no significant 
differences between weeks 8 and 12 (p > 0.05). It was concluded 
that the onset time of clonidine may be after the first 4 weeks, 
and the peak time may be at 8–12 weeks. It has been suggested 
that clonidine needs to be taken for a longer period (3 weeks or 
more) than haloperidol to lead to improvement (26, 27). Thus, 
withdrawal should not be undertaken because of ineffectiveness 
within a short time. It has been reported that medications for 
treatment of TD are helpful initially and have a noticeable effect 
but leave tics unchanged or worsened after approximately a year 
or 6  months (28). Our long-term follow-up of 8–17  months 
showed that 38.1% (8/21) of patients who were treated with a 
clonidine transdermal patch achieved complete remission of tics 
and were relapse free. Thus, clonidine had definite efficacy in the 
long term.
Further analysis of all factors of YGTSS score-reducing 
rates at different periods showed that compared with the level 
of 25% reduction, there were no significant differences in 
the score-reducing rate of four factors, including motor tics, 
phonic tics, total tics, and overall impairment, at 4 and 8 weeks. 
Compared with the level of 25%, there were significant differ-
ences in the score-reducing rate of motor tics and total tics at 
12 weeks. This finding suggested that a clonidine transdermal 
patch could improve motor tics but had poor efficacy for phonic 
tics and overall impairment ratings. This finding is similar to 
the results of studies by Leckman et al. (29, 30) and Du et al. 
(24). Clonidine is more effective for motor tics than for phonic 
tics, which may be because motor tics are less influenced by 
psychological factors.
The conditional fluctuation of tics was frequent, and indi-
vidual differences were remarkable. Treatment protocols should 
be individualized and analyzed by synthesis according to treat-
ment history, course of the disease, classification, comorbidities, 
and age (16). Our model showed that the first three important 
independent variables affecting treatment were classification 
(100%), course of the disease (78.1%), and motor tics (40.4%). 
Hanna (31) suggested that dopamine antagonists should be used 
in treating severe cases and (or) when other pharmaceutical 
treatments failed to improve the tics. Clonidine can be used as 
the first-line treatment for mild to moderate cases, especially for 
children and patients receiving initial treatment. Other stud-
ies (32–34) have suggested that clonidine can also be used as 
refractory and (or) in severe cases or cases with co-occurring 
ADHD. Our forecast analysis showed that there was an efficacy 
of 100% for treatment with a clonidine transdermal patch if the 
clinical course was ≤24 months and motor tic score was <16. The 
efficacy was only 57.1% if the clinical course was ≤24 months 
and the motor tic score was >16. There was an efficacy of 62.5% 
if the clinical course was >24 months and clinical classification 
was CTD. However, 90% of patients who were treated with a 
clonidine transdermal patch were invalid if the clinical course 
was >24 months and clinical classification was TS. This finding 
provides the basis for the conditions in which clonidine trans-
dermal patch treatment should be chosen. However, there was 
a limitation in the predictive value of the model because of the 
small sample size.
Haloperidol is often poorly tolerated in TD, with only 20–30% 
of patients continuing to take this medication over time (35) 
secondary to the serious side effects. Clonidine, however, often 
has good tolerance (13–15, 22, 24, 26, 30, 36). The most common 
adverse events with clonidine are sedation and dizziness, which 
often tend to be mild to moderate in severity (16, 26) without 
evidence of other adverse effects, including cardiac toxicity 
(16). In our study, the most common adverse events were rash 
(33.3%, 7/21), slight dizziness and headache (9.5%, 2/21); no 
patients dropped out of treatment due to adverse effects. In our 
long-term follow-up of 8–17 months, 56.7% (21/37) of patients 
continued to take this medication after the 12-week test. This 
result implies that clonidine has good tolerance and a high level 
of safety over time.
Our study was an open-label trial that was not placebo 
controlled. It could be argued that the findings were the result 
of a placebo effect rather than reflecting the intrinsic activity of 
the study drugs. However, compared with other diseases with a 
psychological origin, TD intrinsically has a lower placebo effect 
(37, 38). The duration of illness for the enrolled children ranged 
from 2 months to several years or longer, and there were no good 
responses to D2-dopamine receptor antagonists. Furthermore, 
placebo effects often do not last long. In our study, clonidine 
continued to improve the symptoms of TD for the 4–12 weeks 
of the study period and maintained its effects in the long-term 
follow-up.
In conclusion, when patients were pretreated with a 
D2-dopamine receptor antagonist that was ineffective or not tol-
erated well, switching to a clonidine transdermal patch treatment 
was effective and safe. A clonidine transdermal patch could be 
a first-line medication for mild and moderate TD cases that are 
characterized by motor tics.
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